Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Inotuzumab ozogamicin (Besponsa®)	MP-RX-FP-12-23	☒ MMM MA ☒ MMM Multihealth

Service Category

☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures
☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Part B Drugs

Service Description

This document addresses the use of Inotuzumab ozogamicin (Besponsa a CD22-directed antibody-drug conjugate (ADC) approved by the Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Background Information

Besponsa is an antibody-drug conjugate composed of a monoclonal antibody targeting CD22 and the cytotoxic agent calicheamicin, which is released into the malignant cells upon binding. It is used to treat acute lymphoblastic leukemia (ALL), and should only be used in CD22+ B-cell ALL due to its molecular target.

The FDA approved Besponsa for CD22+ B-cell precursor ALL based on a phase 3 study (Kantarjian 2017). Besponsa monotherapy was compared to investigator's choice of standard therapy for patients age 18 years or older with relapsed or refractory, philadelphia chromosome (Ph)- positive or Ph-negative ALL. All patients had an Eastern Cooperative Oncology Group Performance Status (ECOG) of ≤2. Though only FDA approved for use in adults, the National Comprehensive Cancer Network® (NCCN) guidelines on Pediatric ALL recommend treatment with Besponsa for younger individuals as well. NCCN additionally recommends the use of Besponsa in combination with a tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, or ponatinib) or mini-hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine) with or without blinatumumab in the relapse/refractory setting. NCCN also recommends Besponsa as induction therapy for Philadelphia chromosome-negative disease in combination with mini-hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine).

Besponsa has a black box warning for hepatotoxicity, including fatal and life-threatening hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS). Risk of VOD was greater in patient who underwent hematopoietic stem cell transplant (HSCT) after Besponsa treatment; other risk factors include liver disease, increased age, later salvage lines, and a greater number of Besponsa treatment cycles. Besponsa should be permanently discontinued if VOD occurs. Besponsa also has a black box warning for increased risk of post-HSCT non-relapse mortality because day 100 post-HSCT mortality was higher in patients receiving Besponsa.

Definitions and Measures

- Line of Therapy:
    - First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.

Policy Name	Policy Number	Scope
Inotuzumab ozogamicin (Besponsa®)	MP-RX-FP-12-23	☒ MMM MA ☒ MMM Multihealth

- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.

- Complete Response (CR): defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets ≥ 100 × 109/L and absolute neutrophil counts [ANC] ≥ 1 × 109/L) and resolution of any extramedullary disease.
- Complete Response with incomplete Hematological Recovery (Cri) is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets < 100 × 109/L and/or ANC < 1 × 109/L) and resolution of any extramedullary disease.
- Minimal Residual Disease (MRD) negativity. Minimal Residual Disease (MRD) refers to the small number of cancer cells that may remain in a patient's body after treatment for a hematologic malignancy, such as leukemia or lymphoma. MRD testing is used to detect and quantify these residual cancer cells. MRD negativity means that the treatment has been successful in reducing the cancer cells to undetectable levels or very low levels. MRD negativity is often associated with a better prognosis and an increased likelihood of long-term remission or cure.

Approved Indications

Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Other Uses

See Background section above.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J9229	Injection, inotuzumab ozogamicin, 0.1 mg [Besponsa]

ICD-10	Description
C91.00-C91.02	Acute lymphoblastic leukemia (ALL)
D46.A	Refractory cytopenia with multilineage dysplasia

Policy Name	Policy Number	Scope
Inotuzumab ozogamicin (Besponsa®)	MP-RX-FP-12-23	☒ MMM MA ☒ MMM Multihealth

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Inotuzumab ozogamicin (Besponsa®)

A. Criteria For Initial Approval

i. Individual has a diagnosis of CD22+ B-cell acute lymphocytic leukemia (ALL); **AND**

ii. Individual meets all of the following:

A. Relapsed or refractory disease; **AND**

B. Individual is using Besponsa as (NCCN 1/2A):

1. A single agent; **OR**
2. In combination with a tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, or ponatinib); **OR**
3. In combination with mini-hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine) with or without blinatumomab;

OR

iii. Individual has a diagnosis of CD22+ B-cell acute lymphocytic leukemia (ALL) (NCCN 2A); **AND**

A. Individual is using Besponsa as induction therapy for Philadelphia chromosome-negative disease; **AND**

B. Individual is using Besponsa in combination with mini-hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine).

B. Criteria For Continuation of Therapy

i. MMM considers subsequent cycles of Besponsa clinically appropriate when there is no evidence of unacceptable toxicity or disease progression, and the recommended maximum duration of therapy has not been exceeded. The following information should be submitted for reauthorization:

A. Documentation from the treating physician showing no progression of disease.

B. Documentation indicating whether the patient achieved CR or CRi (see Background section above for definitions).

ii. For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with Besponsa is 2 cycles.

A. MMM considers a third cycle of Besponsa medically appropriate for patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles. In this setting, the following information should be submitted for reauthorization:

1. Documentation on whether the patient achieved CR or CRi.

2. Documentation on whether the patient achieved minimal residual disease (MRD) negativity after the first two 2 cycles.

iii. For all other patients not proceeding to HSCT, additional cycles of treatment, up to a maximum of 6 cycles, may be approved.

A. In accordance with Besponsa's FDA approved labeling, MMM does not consider continuation of treatment with Besponsa medically appropriate in patients who fail to achieve a CR or CRi within 3 cycles.

C. Authorization Duration

i. Initial Approval Duration: Up to a maximum of 1 cycle (3-4 weeks)

ii. Reauthorization Approval Duration: Up to a maximum of 1 cycle (4 weeks)

D. **Conditions Not Covered**

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

i. Requests for Besponsa (inotuzumab ozogamicin) may not be approved if the above criteria (Section A: Criteria for Initial Approval) are not met and for all other indications not included above.

Limits or Restrictions

A. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

i. Cycle 1 of the treatment regimen is designed to last for 3 weeks (21 days). However, it can be extended to 4 weeks (28 days) under specific circumstances:

A. If the patient achieves Complete Remission (CR) or Complete Remission with incomplete hematologic recovery (CRi), an extension to a 4-week cycle is considered. In this case, treatment will be administered on Days 1, 8, and 15, with a 7-day treatment-free interval starting on Day 21.

B. An extension to a 4-week cycle may also be warranted to allow for toxicity recovery. In this scenario, a 7-day treatment-free interval starting on Day 21 is recommended.

ii. Subsequent treatment cycles have a duration of 4 weeks, with treatment administered on Days 1, 8, and 15, followed by a 7-day treatment-free interval starting on Day 21. Recommended dose depends on the patient's response to treatment.

iii. Discontinuation is recommended in patients who fail to achieve a CR or CRi within 3 cycles.

Policy Name	Policy Number	Scope
Inotuzumab ozogamicin (Besponsa®)	MP-RX-FP-12-23	☒ MMM MA ☒ MMM Multihealth

	Day 1	Day 8	Day 15
Cycle 1			
Dose[a]	0.8 mg/m^2	0.5 mg/m^2	0.5 mg/m^2
Cycle length	21 days. Can be extended to 28 days in patients who have achieved CR or CRi, and/or to allow for recovery from toxicity (7-day treatment-free interval starting on Day 21)		
Subsequent Cycles in Patients who achieve CR[b] or CRi[c]			
Dose[a]	0.5 mg/m^2	0.5 mg/m^2	0.5 mg/m^2
Cycle length	28 days[d]		
Subsequent Cycles in Patients who have not achieved CR[b] or CRi[c]			
Dose[a]	0.8 mg/m^2	0.5 mg/m^2	0.5 mg/m^2
Cycle length	28 days[d]		
Exceptions			
None			

[a] Dose is based on the patient's Body Surface Area (BSA).
[b] CR is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets ≥ 100 × 109/L and absolute neutrophil counts [ANC] ≥ 1 × 109/L) and resolution of any extramedullary disease.
[c] CRi is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets < 100 × 109/L and/or ANC < 1 × 109/L) and resolution of any extramedullary disease.
[d] 7-day treatment-free interval starting on Day 21.

Reference Information

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: January 20, 2023.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375(8):740-753.
4. Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018;19:240- 248.
5. Jabbour E, Ravindi F, Kebriaei P, et al. Salvage chemoinnunotherapy with inotuzumab ozogamicin combined with mini-Hyper-CVD for patients with relapsed or refractory Philadephia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial. JAMA oncol 2018; 4:230-234.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
7. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on January 20, 2023.
    a. Pediatric Acute lymphoblastic Leukemia. V1.2023. Revised November 9, 2022.
    b. Acute Lymphoblastic Leukemia. V1.2022. Revised April 4, 2022.

Policy Name	Policy Number	Scope
Inotuzumab ozogamicin (Besponsa®)	MP-RX-FP-12-23	☒ MMM MA ☒ MMM Multihealth

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023

Revised: 11/6/2023